$NATR

NATR Financials: Revenue Breakdown, Margins & Competitor Comparison

Nature's Sunshine Products Inc (NATR) generates most of its revenue from the General Health segment, contributing 41.3% or $47.38M of total sales, followed by Digestive and Cardiovascular segments. The company demonstrates strong profitability with a gross margin of 72.52%, an operating margin of 4.30%, and a net margin of 3.65%, alongside a 12.32% Return on Equity. NATR, with a market capitalization of $462.55M, outperforms competitors like NAGE in gross margin but trails USNA.

Original reporting
Published Apr 9, 2026, 4:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 9, 2026, 5:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$NATR
Bullish
high confidence
Mentioned
$NATR
alphai data visualization · based on Intellectia AI
Decision brief

The 30-second read

$NATRBullishMed
01

Why it matters

Strong margins and positive sentiment suggest favorable trading conditions, but margins are not exceptionally high, warranting cautious optimism.

02

Market read

The company's financial health and positive sentiment make it a relevant candidate for short-term trading strategies within the health sector.

03

What to watch

Competitive pressures, regulatory changes, or shifts in consumer preferences could negatively impact future performance.

Timing: short-term (next 1-4 weeks)

Background

NATR's financials reveal a focus on the General Health segment, which is performing well amidst industry growth.

Company-level read

Ticker impact

$NATRBullishHigh confidence
Context

Primary focus of the news due to detailed financials and positive sentiment.

Expected impact

Moderate upward movement in the near term (1-3 weeks), contingent on broader market conditions.

Evidence & confidence

The company's solid margins, favorable sentiment score (0.40 bullish), and outperforming gross margin relative to competitors suggest a positive outlook. However, operating margin and net margin are modest, indicating some caution.

Market effects

The health and wellness sector may experience increased investor interest, especially in companies with strong margins.

Limited regional impact; primarily relevant to North American markets where NATR operates.

Moderate; health sector trends can influence global wellness product markets.

Counterpoint

Potential overvaluation if broader market conditions deteriorate or if margins decline due to increased costs.

Key entities

  • Nature's Sunshine Products Inc

    A wellness company specializing in health supplements.

  • NATR

    Stock symbol for Nature's Sunshine Products Inc.

Related articles

$NATRMedAI 8/10

Nature's Sunshine (NATR) Stock Trades Down, Here Is Why

Nature’s Sunshine (NASDAQ: NATR) shares fell 17.7% after the company reported Q2 2026 results that missed Wall Street. Revenue was $117 million, 5.4% below estimates, and adjusted EPS was $0.21, 22.2% below expectations. It also cut full-year revenue guidance to $495 million at the midpoint, down 2.5% from prior guidance.

$NATRMed

NATURES SUNSHINE PRODUCTS INC (NATR): Results of Operations and Financial Condition

NATURES SUNSHINE PRODUCTS INC (NATR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 3 natrq22026earningsrelease.htm EX-99.1 Document Nature's Sunshine Reports Second Quarter 2026 Results Net Sales up 2% to $117.0 million, Gross Profit Margin up 194 Basis Points to 73.7% LEHI, Utah – August 6, 2026 – Nature’s Sunshine Products, Inc. (Nasdaq: NATR) ("Natur

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

$SUNEMedAI 8/10

Pentagon to invest $400m in Australian rare earth mine

Sunrise Energy Metals said the US Pentagon will provide a conditional $400 million loan commitment to develop Syerston, a proposed scandium mine in Fifield, NSW. The project targets Western supply of scandium used in defence and other sectors amid China’s export restrictions. Sunrise also said it has a deal with Lockheed Martin for 25% of output for five years.